SCHOTT Pharma celebrates first anniversary as a listed company on Frankfurt Stock Exchange

On 28 September 2023, SCHOTT Pharma CEO Andreas Reisse and CFO Dr. Almuth Steinkühler, surrounded by hundreds of cheering employees, rang in the new chapter of the company’s history on the trading floor of the Frankfurt Stock Exchange. Just two months later, SCHOTT Pharma was admitted to the SDAX index, and in September 2024, climbed up the ranks to join the MDAX index. These achievements reflect the strong market confidence in SCHOTT Pharma’s growth trajectory and commitment to expansion and innovation and are testament to its attractive business model.

Over the past year, SCHOTT Pharma has initiated and progressed with ambitious projects to expand its network of production sites in Europe and the United States. These projects are set to enhance its global production footprint to meet the growing demand for innovative pharma drug containment solutions and delivery systems.

Innovation remains at the core of SCHOTT Pharma’s strategy. Since its IPO in September 2023, the company has launched several state-of-the-art products, including SCHOTT EVERIC® freeze, SCHOTT TOPPAC® Nest 160, as well as large volume cartriQ® ready-to-use (RTU) cartridges. These products underscore SCHOTT Pharma’s commitment to advancing solutions for the key trends in the healthcare industry.

“As we reflect on our achievements over the past year, we extend our gratitude to our internal team, our customers and partners, and shareholders for their unwavering support. We look forward to continuing our growth journey, driving value for all our stakeholders,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

For additional news about SCHOTT Pharma please visit our media center.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023.